My Profile e-Learning Center my.ASTHO Contact Us

Filter Results

Clear All Filters

Topic

Product Type

Location

Contributor

Published Date

Displaying 3 results for

GO
Search Filters: Overdose Prevention cancel Florida cancel Social and Behavioral Health cancel

Building Capacity and Dedicating Field Staff to Address Substance Use Disorders During COVID-19

COVID and Special Populations,
COVID and Mental Health,
Opioids,
Overdose Prevention,
Maternal Morbidity and Mortality,
Kentucky,
Ohio,
Nevada,
Florida,
Washington,
Blog,
Ramya Dronamraju,
Sanaa Akbarali,
Risk-Appropriate Care,
Partnership,
Women, Infant, Family Health Mental Health,
OMNI

In 2020, the COVID-19 pandemic exacerbated barriers to care and treatment for individuals experiencing opioid use disorder. Experts estimate a record-setting 90,000 people died of a drug overdose in ...

ASTHO’s 2024 Legislative Session Update: Part One

Data Modernization,
Arizona,
Health Policy Update,
State Health Policy,
Health Equity,
Environmental Health,
New Hampshire,
Oklahoma,
Maine,
Florida,
Colorado,
Tennessee,
Virginia,
Wisconsin,
California,
New Jersey,
Missouri,
Maryland,
New York,
Georgia,
Delaware,
New Mexico,
Hawaii,
Overdose Prevention,
STIs,
Infant and Child Health,
Lillian Colasurdo,
Maggie Davis,
Lana McKinney,
JoAnne McClure

ASTHO’s 2024 Legislative Session Update: Part One legislative session, state policy, data collection, domestic violence, health information exchange, data privacy, substance misuse, overdose ...

How the Emergence of Xylazine Impacts Overdose Prevention Policy

State Health Policy,
Overdose Prevention,
Alaska,
Colorado,
Guam,
Maine,
Maryland,
Nebraska,
New York,
Northern Mariana Islands,
Pennsylvania,
South Carolina,
Vermont,
Illinois,
New Hampshire,
Delaware,
New Jersey,
Florida,
Massachusetts,
Utah,
Michigan,
Rhode Island,
Oklahoma,
West Virginia,
Indiana,
Puerto Rico,
JoAnne McClure,
Victoria Pless,
Health Policy Update,
Ohio

How the Emergence of Xylazine Impacts Overdose Prevention Policy overdose prevention policy, overdose crisis, fatal overdoses, emergence of xylazine, illicit drug supply, toxicological testing, ...